Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat.

Wrublewsky S., Bickelmann C., Meßmer LS., Wilden C., Berhorst C., Prates-Roma L.

Animal Study on Type 1 Diabetes, published in Diabetes Obes Metab (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Diabetes Obes Metab (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40994084
PMCID
PMC12587261
DOI
10.1111/dom.70127
Citations
1

Abstract (original English)

Aims In the therapy of type 1 diabetes mellitus, the subcutaneous space has been suggested to be a clinically preferable transplantation site for pancreatic islets due to its easy accessibility. However, its poor vascularisation capacity and, thus, challenging environment typically result in islet engraftment failure. In the present proof-of-principle study, we demonstrate that this problem can be overcome by nanofat, an emulsified fat derivative already used in clinical practice. Materials and methods The cellular composition of nanofat was assessed by immunohistochemistry. The angiogenic activity of the soluble and cellular nanofat fraction was analyzed by an angiogenic protein array, tube formation and spheroid sprouting assays. The viability and endocrine function of islets exposed to the nanofat fractions was investigated by flow cytometry, qRT-PCR and ELISA. In vivo, islets and nanofat were co-transplanted under the kidney capsule as well as into the subcutaneous space of diabetic animals. Results In a panel of in vitro assays, we showed that the soluble and cellular nanofat fraction improve the viability, hormone release, and angiogenic activity of islets. The beneficial effects of these two fractions were validated in vivo in the murine diabetic kidney capsule model, as indicated by an accelerated restoration of normoglycaemia. The co-transplantation of islets with nano

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Islets of Langerhans TransplantationAnimalsMiceIslets of LangerhansDiabetes Mellitus, ExperimentalGraft SurvivalDiabetes Mellitus, Type 1Neovascularization, PhysiologicMaleMice, Inbred C57BL

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research